Table 3. Last prior chemotherapy dose continued on study with amuvatinib.
| Subject | Agents | Nominal dose | Total dose (mg) |
|---|---|---|---|
| 001 | Carboplatin Etoposide |
6 (target AUC) 80 (mg/m2)×3 |
660 420 |
| 002 | Carboplatin Etoposide |
5 (target AUC) 100 (mg/m2)×3 |
520 471 |
| 003 | Carboplatin Etoposide |
5 (target AUC) 100 (mg/m2)×3 |
652 201 |
| 004 | Carboplatin Etoposide |
5 (target AUC) 100 (mg/m2)×3 |
473 576 |
| 005 | Carboplatin Etoposide |
5 (target AUC) 100 (mg/m2)×3 |
619 606 |
| 006 | Carboplatin Etoposide |
6 (target AUC) 100 (mg/m2)×3 |
570 570 |
| 007 | Carboplatin Etoposide |
6 (target AUC) 80 (mg/m2)×3 |
640 477 |
| 008 | Carboplatin Etoposide |
5 (target AUC) 100 (mg/m2)×3 |
640 600 |
| 009 | Carboplatin Etoposide |
5 (target AUC) 100 (mg/m2)×3 |
672 555 |
| 010 | Cisplatin Etoposide |
100 (mg/m2)×3 | 152.25 480 |
| 011 | Carboplatin Etoposide |
3.75 (target AUC) 45 (mg/m2)×1 |
318 70 |
| 012 | Carboplatin Etoposide |
5 (target AUC) 100 (mg/m2)×3 |
620 630 |
| 013 | Cisplatin Etoposide |
100 (mg/m2)×3 | 147 588 |
| 014 | Cisplatin Etoposide |
120 (mg/m2)×3 | 101 600 |
| 015 | Cisplatin Etoposide |
100 (mg/m2)×3 | 100 501 |
| 016 | Carboplatin Etoposide |
6 (target AUC) 80 (mg/m2)×3 |
490 387 |
| 017 | Cisplatin Etoposide |
100 (mg/m2)×2 | 84 336 |
| 018 | Cisplatin Etoposide |
100 (mg/m2)×3 | 158 630 |
| 019 | Carboplatin Etoposide |
5 (target AUC) 100 (mg/m2)×3 |
653 501 |
| 020 | Carboplatin Etoposide |
6 (target AUC)100 (mg/m2)×3 | 737 540 |
| 023 | Cisplatin Etoposide |
120 (mg/m2)×3 | 127 765 |
| 024 | Carboplatin Etoposide |
6 (target AUC) 100 (mg/m2)×3 |
900 585 |